Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
Codexis, Inc. filed this Current Report on Form 8-K on August 30, 2011, regarding a material definitive agreement. The company is incorporated in Delaware and maintains its principal executive offices in Redwood City, California.
Key Financial Metrics
This filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a contractual amendment.
Material Changes
On August 30, 2011, the Company entered into an amendment (the "Grant Amendment") to a grant awarded by the Economic Development Board of Singapore (EDB). Key changes include:
- Expanded Scope: The amendment permits the scope of research activities qualifying for reimbursement to include chemical and water industry projects, in addition to the previously focused pharmaceutical research and development.
- Extended Term: The term of the Grant is extended by one year, now ending on March 31, 2013.
- Expense Confirmation: The amendment confirms the list of expenses that qualify for reimbursement under the Grant.
Outlook, Risks, and Management Commentary
The filing states that the summary provided is not a complete description of the rights and obligations of the parties. The full Grant Amendment will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2011. No specific risks, contingencies, or unusual items were detailed in this text beyond the standard qualification regarding the summary nature of the disclosure.
Investor Verification Points
- Verify the specific list of reimbursable expenses confirmed in the Grant Amendment.
- Review the full text of the Grant Amendment when filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2011.
- Assess the potential financial impact of expanding the Singapore facility's scope to chemical and water industry projects.